Published On: Wed, Oct 19th, 2016

Mesoblast Limited (NASDAQ:MESO) Updated Analyst Coverage


A number of investment brokers have recently updated their price targets on shares of Mesoblast Limited (NASDAQ:MESO).

Most recent broker ratings

07/05/2016 – Mesoblast Limited had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 14 price target on the stock.

06/14/2016 – Mesoblast Limited was downgraded to “neutral” by analysts at Credit Suisse. They now have a USD 5 price target on the stock.

03/07/2016 – Mesoblast Limited was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 10 price target on the stock.

02/19/2016 – Chardan Capital began new coverage on Mesoblast Limited giving the company a “neutral” rating. They now have a USD 5.5 price target on the stock.

11/24/2015 – Mesoblast Limited had its “buy” rating reiterated by analysts at Ladenburg Thalmann.

The share price of Mesoblast Limited (NASDAQ:MESO) was up +1.46% during the last day of trading, with a day high of 4.26. 6838 shares were traded during the last session.

The stock’s 50 day moving average is 4.53 and its 200 day moving average is 5.75. The stock’s market capitalization is 315.90M. Mesoblast Limited has a 52-week low of 3.50 and a 52-week high of 13.00.

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.